arrow_back Civic Audit
Share share

New Rules for Pediatric Cancer Drug Research

This act aims to accelerate research into new cancer drugs for children, especially molecularly targeted therapies. It changes drug testing rules to give children faster access to innovative treatments, potentially improving their chances of recovery.
Key points
Requires pharmaceutical companies to conduct pediatric cancer drug investigations if the drug is for adults and has potential for pediatric cancers.
Allows testing of new drug combinations not previously approved, paving the way for more effective therapies.
Introduces a requirement for preclinical studies to better understand how drugs affect pediatric cancers.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Print number: 117_HR_6972
Sponsor: Rep. Butterfield, G. K. [D-NC-1]
Process start date: 2022-03-08
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Give Kids a Chance Act of 2022

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_6972.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-03-08.

What are the main provisions?

Key points include:

  • Requires pharmaceutical companies to conduct pediatric cancer drug investigations if the drug is for adults and has potential for pediatric cancers.
  • Allows testing of new drug combinations not previously approved, paving the way for more effective therapies.
  • Introduces a requirement for preclinical studies to better understand how drugs affect pediatric cancers.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Butterfield, G. K. [D-NC-1].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

What is the impact of this bill?

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.

CATEGORIES

Health